CHA <sub>2</sub> DS <sub>2</sub> -VASc Score for Identifying Truly Low-Risk Atrial Fibrillation for Stroke
-
- Tae-Hoon Kim
- From the Division of Cardiology, Department of Internal Medicine, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea (T.-H.K., P.-S.Y., D.K., H.T.Y., J.-S.U., J.-Y.K., H.-N.P., M.-H.L., B.J.); Institute of Cardiovascular Sciences, University of Birmingham, United Kingdom (G.Y.H.L.); and Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Denmark (G.Y.H.L.).
-
- Pil-Sung Yang
- From the Division of Cardiology, Department of Internal Medicine, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea (T.-H.K., P.-S.Y., D.K., H.T.Y., J.-S.U., J.-Y.K., H.-N.P., M.-H.L., B.J.); Institute of Cardiovascular Sciences, University of Birmingham, United Kingdom (G.Y.H.L.); and Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Denmark (G.Y.H.L.).
-
- Daehoon Kim
- From the Division of Cardiology, Department of Internal Medicine, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea (T.-H.K., P.-S.Y., D.K., H.T.Y., J.-S.U., J.-Y.K., H.-N.P., M.-H.L., B.J.); Institute of Cardiovascular Sciences, University of Birmingham, United Kingdom (G.Y.H.L.); and Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Denmark (G.Y.H.L.).
-
- Hee Tae Yu
- From the Division of Cardiology, Department of Internal Medicine, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea (T.-H.K., P.-S.Y., D.K., H.T.Y., J.-S.U., J.-Y.K., H.-N.P., M.-H.L., B.J.); Institute of Cardiovascular Sciences, University of Birmingham, United Kingdom (G.Y.H.L.); and Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Denmark (G.Y.H.L.).
-
- Jae-Sun Uhm
- From the Division of Cardiology, Department of Internal Medicine, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea (T.-H.K., P.-S.Y., D.K., H.T.Y., J.-S.U., J.-Y.K., H.-N.P., M.-H.L., B.J.); Institute of Cardiovascular Sciences, University of Birmingham, United Kingdom (G.Y.H.L.); and Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Denmark (G.Y.H.L.).
-
- Jong-Youn Kim
- From the Division of Cardiology, Department of Internal Medicine, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea (T.-H.K., P.-S.Y., D.K., H.T.Y., J.-S.U., J.-Y.K., H.-N.P., M.-H.L., B.J.); Institute of Cardiovascular Sciences, University of Birmingham, United Kingdom (G.Y.H.L.); and Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Denmark (G.Y.H.L.).
-
- Hui-Nam Pak
- From the Division of Cardiology, Department of Internal Medicine, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea (T.-H.K., P.-S.Y., D.K., H.T.Y., J.-S.U., J.-Y.K., H.-N.P., M.-H.L., B.J.); Institute of Cardiovascular Sciences, University of Birmingham, United Kingdom (G.Y.H.L.); and Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Denmark (G.Y.H.L.).
-
- Moon-Hyoung Lee
- From the Division of Cardiology, Department of Internal Medicine, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea (T.-H.K., P.-S.Y., D.K., H.T.Y., J.-S.U., J.-Y.K., H.-N.P., M.-H.L., B.J.); Institute of Cardiovascular Sciences, University of Birmingham, United Kingdom (G.Y.H.L.); and Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Denmark (G.Y.H.L.).
-
- Boyoung Joung
- From the Division of Cardiology, Department of Internal Medicine, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea (T.-H.K., P.-S.Y., D.K., H.T.Y., J.-S.U., J.-Y.K., H.-N.P., M.-H.L., B.J.); Institute of Cardiovascular Sciences, University of Birmingham, United Kingdom (G.Y.H.L.); and Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Denmark (G.Y.H.L.).
-
- Gregory Y.H. Lip
- From the Division of Cardiology, Department of Internal Medicine, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea (T.-H.K., P.-S.Y., D.K., H.T.Y., J.-S.U., J.-Y.K., H.-N.P., M.-H.L., B.J.); Institute of Cardiovascular Sciences, University of Birmingham, United Kingdom (G.Y.H.L.); and Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Denmark (G.Y.H.L.).
書誌事項
- タイトル別名
-
- A Korean Nationwide Cohort Study
説明
<jats:sec> <jats:title>Background and Purpose—</jats:title> <jats:p> As the threshold of stroke risk for initiating oral anticoagulants is lowered after the introduction of the nonvitamin K antagonist oral anticoagulants, the focus of stroke prevention in patients with nonvalvular atrial fibrillation has shifted away from predicting high-risk patients toward initially identifying patients with a truly low risk of ischemic stroke, who do not need antithrombotic therapy. We tested the predictive ability of the congestive heart failure, hypertension, age ≥75, diabetes mellitus, prior stroke or transient ischemic attack (doubled; CHADS <jats:sub>2</jats:sub> ), congestive heart failure, hypertension, age ≥75 (doubled), diabetes mellitus, prior stroke or transient ischemic attack (doubled), vascular disease, age 65 to 74, female (CHA <jats:sub>2</jats:sub> DS <jats:sub>2</jats:sub> -VASc), and Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) risk stratification schemes in oral anticoagulants naive patients with atrial fibrillation in a Korean nationwide sample cohort. </jats:p> </jats:sec> <jats:sec> <jats:title>Methods—</jats:title> <jats:p>From January 2002 to December 2008, a total of 5855 oral anticoagulant naive patients with nonvalvular atrial fibrillation aged ≥20 years were enrolled from Korea National Health Insurance Service-Sample Cohort database and were followed-up until December 2013.</jats:p> </jats:sec> <jats:sec> <jats:title>Results—</jats:title> <jats:p> At baseline, the proportions categorized as low risk using CHADS <jats:sub>2</jats:sub> , CHA <jats:sub>2</jats:sub> DS <jats:sub>2</jats:sub> -VASc, and ATRIA risk stratification schemes were 1049 (17.9%), 860 (14.7%), and 3280 (56.0%), respectively. During follow-up, the low-risk category using CHADS <jats:sub>2</jats:sub> , CHA <jats:sub>2</jats:sub> DS <jats:sub>2</jats:sub> -VASc, and ATRIA scores was retained in 811 (13.9%), 667 (11.4%), and 2729 (46.6%) patients, respectively. Rates of ischemic stroke (100 person-years) in the low risk categories of CHADS <jats:sub>2</jats:sub> , CHA <jats:sub>2</jats:sub> DS <jats:sub>2</jats:sub> -VASc, and ATRIA scores were 0.42, 0.26, and 1.43, respectively. CHA <jats:sub>2</jats:sub> DS <jats:sub>2</jats:sub> -VASc had the best sensitivity (98.8% versus 85.7% in CHADS <jats:sub>2</jats:sub> and 74.8% in ATRIA) and negative predictive value (98.8% versus 95.3% for CHADS <jats:sub>2</jats:sub> and 93.7% for ATRIA) for the prediction of stroke incidence and was best for the prediction of the absence of ischemic stroke during 5 years of follow-up (odds ratio, 16.4 [95% confidence interval, 8.8–30.8]). </jats:p> </jats:sec> <jats:sec> <jats:title>Conclusions—</jats:title> <jats:p> The CHA <jats:sub>2</jats:sub> DS <jats:sub>2</jats:sub> -VASc score shows good performance in defining truly low-risk Asian patients with atrial fibrillation for stroke compared with CHADS <jats:sub>2</jats:sub> and ATRIA scores. </jats:p> </jats:sec>
収録刊行物
-
- Stroke
-
Stroke 48 (11), 2984-2990, 2017-11
Ovid Technologies (Wolters Kluwer Health)
